Subcutaneous Dosing and Supporting Adherence at Home

Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center notes that subcutaneous amivantamab is given over roughly 5 minutes with fewer administration-related reactions, which matters at satellite sites, and that the weekly loading month creates repeated chances to reinforce skin care and antibiotic teaching in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC). Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute agrees that patients cannot absorb everything in one visit, and says the choice between subcutaneous and intravenous administration is not a close call, citing the survival benefit, absence of infusion reactions and lower venous thromboembolism rates. On adherence for a patient living alone managing lotions, antibiotics and anticoagulation, he says he does not police compliance but supports what patients can manage, adjusts at the edges, and tells them the patients he worries about are the ones who do not call.